Patents Assigned to Galderma Research & Development
  • Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
    Patent number: 9650337
    Abstract: A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 16, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Branislav Musicki
  • Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
    Patent number: 9630949
    Abstract: The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 25, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Bouix-Peter, Itaru Suzuki, Nicolas Rodeville, Pascale Mauvais, Jean-Claude Pascal
  • Method for the treatment of acne using pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
    Patent number: 9622994
    Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: April 18, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michael Graeber, Janusz Czernielewski
  • Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders
    Patent number: 9610461
    Abstract: A system comprising a combination of at least one MCI R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 4, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Carole Chomat, Philippe Martel, Johannes Voegel
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
    Patent number: 9580412
    Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 28, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Method for preventing or treating skin tumor
    Patent number: 9554988
    Abstract: Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an ? adrenergic receptor agonist, such as brimonidine.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 31, 2017
    Assignee: Galderma Research & Development
    Inventors: Guy Bouvier, Matthew James Leoni, Michael Graeber
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
    Patent number: 9526732
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds represented by the general formula (I) are described. Also described, are pharmaceutical compositions including these compounds and the use of these compounds and compositions for the treatment of chemokine-mediated pathologies.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Phenol derivatives and pharmaceutical or cosmetic use thereof
    Patent number: 9505720
    Abstract: The present invention relates to novel compounds of general formula: and to the cosmetic or pharmaceutical use thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 29, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Cédric Poinsard, Pascal Collette, Jean-Michel Linget, Sandrine Rethore, Pascale Mauvais
  • PULSE PHOTODYNAMIC TREATMENT OF ACNE
    Publication number: 20160339222
    Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of acne is described herein.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 24, 2016
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Hans Christian WULF
  • Combination child-resistant package and collapsible tube, and method of using same
    Patent number: 9499310
    Abstract: A combination includes a child-resistant package and a collapsible tube removably positionable therein. A sidewall of a body of the package has an interior surface and an opposing exterior surface. A cavity is defined by the body. An opening is positioned proximate an open first end of the body. A bottom wall is positioned proximate an open second end of the body. A cap is removably mounted onto at least a portion of the first end of the body. The collapsible tube is surrounded by the body, the bottom wall and the cap when the cap is mounted onto at least a portion of the first end of the body. The collapsible tube includes a generally flexible housing defining a cavity for holding a substance to be dispensed from the housing. A closure is removably mounted onto the housing.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 22, 2016
    Assignee: Galderma Research & Development
    Inventor: Sebastien Fily
  • Topical compositions in the form of a gel containing a particular solubilized retinoid
    Patent number: 9498465
    Abstract: A composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: November 22, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Agnès Duprat, Claire Mallard
  • Pharmaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith
    Patent number: 9452126
    Abstract: Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: September 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Marc Moutet, Jean-Claude Yadan
  • N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
    Patent number: 9452120
    Abstract: N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) are described that are potent modulators (e.g., inhibitors) of an androgen receptor, and which are useful, for example, in the treatment of a dermatological disease or disorder; a disease or disorder of the sebaceous gland(s); acne; hyperseborrhoea; oily skin, seborrhoeic dermatitis; hyperpilosity or hirsutism; atopic dermatitis; or androgenic alopecia; especially acne. Also described, are compositions (e.g., pharmaceutical compositions, cosmetic compositions) comprising the compounds; methods of preparing the compositions; methods of modulating (e.g., inhibiting) and androgen receptors using the compounds and/or compositions; and medical and/or cosmetic use of the compounds and compositions.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Cédric Poinsard
  • METHOD FOR EVALUATING THE SEVERITY OF ATROPHIC ACNE SCARS ON A PATIENT AND DEVICE USED TO EVALUATE THE DISTRIBUTION OF ACNE SCARS
    Publication number: 20160235355
    Abstract: A method is described for evaluating the severity of atrophic acne scars in a patient. Also described, is a device for implementing this method. The device can be in the form of a transparent support made of flexible plastic, with suitable dimensions for covering the face of the patient, the support being cross-hatched with same-size adjacent square marked by borders. The use of the device for evaluating the distribution of acne scars on the face of a patient is also described.
    Type: Application
    Filed: March 28, 2014
    Publication date: August 18, 2016
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Laurent PETIT
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
    Patent number: 9415039
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 16, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Patricia Rossio, Marlène Schuppli-Nollet, Laurence Clary, Jean-Guy Boiteau
  • Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions
    Patent number: 9408793
    Abstract: Compounds or salts thereof are described that correspond to general formula (I) below: Also described, are pharmaceutical and cosmetic compositions that include these compounds. Methods of using these compounds and compositions for the treatment of pathological conditions are also described.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: August 9, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Michel Rivier, Gérard Feraille, André Jomard
  • In vitro method using human skin for evaluating the influence of ABC transporters
    Patent number: 9400283
    Abstract: An in vitro method is described that uses full-thickness human skin for evaluating the influence of ABC transporters (such as MDR1, MRP1, MRP2 or BCRP) on the absorption and distribution of topically applied medicinal substances.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 26, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Hanan Osman-Ponchet
  • Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent number: 9387187
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: July 12, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michael Graeber, Janusz Czernielewski
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
    Patent number: 9388149
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 12, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteaux, Laurence Clary, Patricia Rossio, Marléne Schuppli-Nollet
  • Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent number: 9381179
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: July 5, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michael Graeber, Janusz Czernielewski